Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study

Gladys N. Janssens; Maarten A.H. van Leeuwen; Nina W. van der Hoeven; Guus  A. de Waard; Robin Nijveldt; Roberto Diletti; Felix Zijlstra; Clemens von Birgelen; Javier Escaned; Marco Valgimigli; Niels van Royen

doi:10.1007/s12265-016-9691-3

Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study

Gladys N. Janssens, Maarten A.H. van Leeuwen, Nina W. van der Hoeven, Guus A. de Waard, Robin Nijveldt, Roberto Diletti, Felix Zijlstra, Clemens von Birgelen, Javier Escaned, Marco Valgimigli, Niels van Royen

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

62 Downloads (Pure)

Abstract

Microvascular injury is present in a large proportion of patients with ST-elevation myocardial infarction (STEMI) despite successful revascularization. Ticagrelor potentially mitigates this process by exerting additional adenosine-mediated effects. This study aims to determine whether ticagrelor is associated with a better microvascular function compared to prasugrel as maintenance therapy after STEMI. A total of 110 patients presenting with STEMI and additional intermediate stenosis in another coronary artery will be studied after successful percutaneous coronary intervention (PCI) of the infarct-related artery. Patients will be randomized to treatment with ticagrelor or prasugrel for 1 year. FFR-guided PCI of the non-infarct-related artery will be performed at 1 month. Microvascular function will be assessed by measurement of the index of microcirculatory resistance (IMR) in the infarct-related artery and non-infarct-related artery, immediately after primary PCI and after 1 month. The REDUCE-MVI study will establish whether ticagrelor as a maintenance therapy may improve microvascular function in patients after revascularized STEMI.

Original language	English
Pages (from-to)	249-256
Journal	Journal of cardiovascular translational research
Volume	9
Issue number	3
DOIs	https://doi.org/10.1007/s12265-016-9691-3
Publication status	Published - 2016

Keywords

IR-100388
METIS-316645
Ticagrelor
Prasugrel
Microvascular injury
ST-elevation myocardial infarction
Adenosine

Access to Document

10.1007/s12265-016-9691-3

Janssens2016reducingFinal published version, 477 KB

Cite this

Janssens, G. N., van Leeuwen, M. A. H., van der Hoeven, N. W., de Waard, G. A., Nijveldt, R., Diletti, R., Zijlstra, F., von Birgelen, C., Escaned, J., Valgimigli, M., & van Royen, N. (2016). Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. Journal of cardiovascular translational research, 9(3), 249-256. https://doi.org/10.1007/s12265-016-9691-3

Janssens, Gladys N. ; van Leeuwen, Maarten A.H. ; van der Hoeven, Nina W. et al. / Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. In: Journal of cardiovascular translational research. 2016 ; Vol. 9, No. 3. pp. 249-256.

@article{b01d714890834ff29ce824940edc5e7e,

title = "Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study",

abstract = "Microvascular injury is present in a large proportion of patients with ST-elevation myocardial infarction (STEMI) despite successful revascularization. Ticagrelor potentially mitigates this process by exerting additional adenosine-mediated effects. This study aims to determine whether ticagrelor is associated with a better microvascular function compared to prasugrel as maintenance therapy after STEMI. A total of 110 patients presenting with STEMI and additional intermediate stenosis in another coronary artery will be studied after successful percutaneous coronary intervention (PCI) of the infarct-related artery. Patients will be randomized to treatment with ticagrelor or prasugrel for 1 year. FFR-guided PCI of the non-infarct-related artery will be performed at 1 month. Microvascular function will be assessed by measurement of the index of microcirculatory resistance (IMR) in the infarct-related artery and non-infarct-related artery, immediately after primary PCI and after 1 month. The REDUCE-MVI study will establish whether ticagrelor as a maintenance therapy may improve microvascular function in patients after revascularized STEMI.",

keywords = "IR-100388, METIS-316645, Ticagrelor, Prasugrel, Microvascular injury, ST-elevation myocardial infarction, Adenosine",

author = "Janssens, {Gladys N.} and {van Leeuwen}, {Maarten A.H.} and {van der Hoeven}, {Nina W.} and {de Waard}, {Guus A.} and Robin Nijveldt and Roberto Diletti and Felix Zijlstra and {von Birgelen}, Clemens and Javier Escaned and Marco Valgimigli and {van Royen}, Niels",

note = "Open access ",

year = "2016",

doi = "10.1007/s12265-016-9691-3",

language = "English",

volume = "9",

pages = "249--256",

journal = "Journal of cardiovascular translational research",

issn = "1937-5387",

publisher = "Springer",

number = "3",

}

Janssens, GN, van Leeuwen, MAH, van der Hoeven, NW, de Waard, GA, Nijveldt, R, Diletti, R, Zijlstra, F, von Birgelen, C, Escaned, J, Valgimigli, M & van Royen, N 2016, 'Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study', Journal of cardiovascular translational research, vol. 9, no. 3, pp. 249-256. https://doi.org/10.1007/s12265-016-9691-3

Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. / Janssens, Gladys N.; van Leeuwen, Maarten A.H.; van der Hoeven, Nina W. et al.

In: Journal of cardiovascular translational research, Vol. 9, No. 3, 2016, p. 249-256.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study

AU - Janssens, Gladys N.

AU - van Leeuwen, Maarten A.H.

AU - van der Hoeven, Nina W.

AU - de Waard, Guus A.

AU - Nijveldt, Robin

AU - Diletti, Roberto

AU - Zijlstra, Felix

AU - von Birgelen, Clemens

AU - Escaned, Javier

AU - Valgimigli, Marco

AU - van Royen, Niels

N1 - Open access

PY - 2016

Y1 - 2016

N2 - Microvascular injury is present in a large proportion of patients with ST-elevation myocardial infarction (STEMI) despite successful revascularization. Ticagrelor potentially mitigates this process by exerting additional adenosine-mediated effects. This study aims to determine whether ticagrelor is associated with a better microvascular function compared to prasugrel as maintenance therapy after STEMI. A total of 110 patients presenting with STEMI and additional intermediate stenosis in another coronary artery will be studied after successful percutaneous coronary intervention (PCI) of the infarct-related artery. Patients will be randomized to treatment with ticagrelor or prasugrel for 1 year. FFR-guided PCI of the non-infarct-related artery will be performed at 1 month. Microvascular function will be assessed by measurement of the index of microcirculatory resistance (IMR) in the infarct-related artery and non-infarct-related artery, immediately after primary PCI and after 1 month. The REDUCE-MVI study will establish whether ticagrelor as a maintenance therapy may improve microvascular function in patients after revascularized STEMI.

AB - Microvascular injury is present in a large proportion of patients with ST-elevation myocardial infarction (STEMI) despite successful revascularization. Ticagrelor potentially mitigates this process by exerting additional adenosine-mediated effects. This study aims to determine whether ticagrelor is associated with a better microvascular function compared to prasugrel as maintenance therapy after STEMI. A total of 110 patients presenting with STEMI and additional intermediate stenosis in another coronary artery will be studied after successful percutaneous coronary intervention (PCI) of the infarct-related artery. Patients will be randomized to treatment with ticagrelor or prasugrel for 1 year. FFR-guided PCI of the non-infarct-related artery will be performed at 1 month. Microvascular function will be assessed by measurement of the index of microcirculatory resistance (IMR) in the infarct-related artery and non-infarct-related artery, immediately after primary PCI and after 1 month. The REDUCE-MVI study will establish whether ticagrelor as a maintenance therapy may improve microvascular function in patients after revascularized STEMI.

KW - IR-100388

KW - METIS-316645

KW - Ticagrelor

KW - Prasugrel

KW - Microvascular injury

KW - ST-elevation myocardial infarction

KW - Adenosine

U2 - 10.1007/s12265-016-9691-3

DO - 10.1007/s12265-016-9691-3

M3 - Article

VL - 9

SP - 249

EP - 256

JO - Journal of cardiovascular translational research

JF - Journal of cardiovascular translational research

SN - 1937-5387

IS - 3

ER -

Janssens GN, van Leeuwen MAH, van der Hoeven NW, de Waard GA, Nijveldt R, Diletti R et al. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. Journal of cardiovascular translational research. 2016;9(3):249-256. doi: 10.1007/s12265-016-9691-3

Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this